Eli Lilly's Foundayo Launch Puts UK Brokers on Counterfeit and Disclosure Watch

Why a Daily GLP-1 Pill Is Now an Insurance Issue

The daily diabetes and weight-loss pill Foundayo from Eli Lilly went on sale in UK pharmacies on Monday through private prescription, after the Medicines and Healthcare products Regulatory Agency authorised it earlier this month. The UK is the first European market to approve the oral GLP-1 treatment, which is taken once daily with no food or water restrictions.

For insurance brokers, the launch matters less because of the drug itself than because the pill format could draw more people into the GLP-1 market, including those who may seek cheaper and unregulated alternatives. The MHRA seized more than 5,000 unlicensed GLP-1 products in 2025, part of nearly 20 million illegally traded medicine doses removed from circulation that year. Pharmacists and the MHRA warn that oral small-molecule drugs are chemically simpler to produce than peptide-based injectables, making counterfeit pills easier to manufacture. A raid on a Northampton warehouse in October 2025 was described by the MHRA as the largest single seizure of trafficked weight-loss medicines ever recorded worldwide; a second operation at the site in May recovered a further 12,000 doses and led to two arrests.

The claims risk is direct: a client who obtains a counterfeit GLP-1 pill has no verified manufacturing standards, regulated dosage or safety data, and cover may be voided if a claim later involves an adverse event linked to that product. The Health Foundation estimated in February that 2.4 million people in the UK are using GLP-1 medication, while declaration rates at travel insurance purchase run well below that figure. A 2025 Consumer Intelligence survey found more than a quarter of UK adults did not know weight-loss medication needed to be declared when buying insurance.

The National Institute for Health and Care Excellence is due to rule on whether Foundayo should be available on the NHS on November 18. If approved, patient volumes could expand beyond private prescription levels and the disclosure gap would grow with them. That timeline is now the key planning anchor for brokers reviewing life, travel and private medical insurance question sets.

The Disclosure Gap, Counterfeit Supply and the November 18 Decision

Why the pill format widens the disclosure gap

Foundayo's once-daily dosing, with no food or water restrictions, removes a behavioural cue that older oral GLP-1 treatments provide. The oral form of Wegovy must be taken fasting, which creates daily awareness of a prescription; Foundayo carries no equivalent reminder. A client who stops and restarts the drug may not think of that as a change worth disclosing. This is not a theoretical concern: a 2025 Consumer Intelligence survey found more than a quarter of UK adults did not know weight-loss medication needed to be declared when buying insurance. For underwriters, that means a general 'prescribed drugs' catch-all in client-facing screening questions may not be sufficient to capture this risk.

What the MHRA's seizures tell brokers about counterfeit supply

The illicit GLP-1 market has so far been dominated by injectables, but the MHRA has already flagged oral small-molecule drugs as a separate risk because they are chemically simpler to produce. Its seizures of more than 5,000 unlicensed GLP-1 products in 2025, and the Northampton warehouse raids that recovered thousands more doses, show that counterfeit weight-loss medicines are already flowing into UK supply chains. The practical consequence for brokers is that they cannot assume counterfeit exposure is limited to injectable products; the launch of a named pill product gives counterfeiters a new format to copy, and gives clients a new unregulated alternative to seek out.

Why November 18 changes the scale

The NICE ruling on Foundayo for NHS use is the clearest near-term trigger for demand growth. If approved, patient volumes would expand beyond private prescription levels, and the gap between actual GLP-1 use and what policyholders declare would widen with them. The MHRA Yellow Card scheme has logged approximately 150,000 adverse-event reports linked to GLP-1 medicines, with around 15,000 classified as serious. Those figures explain why insurers treat GLP-1 use as medically relevant rather than incidental, and why a larger undeclared user base would translate into more claims disputes.

The product liability angle for pharmacy and distributor clients

Brokers with pharmacy or distributor clients face a second exposure. Standard product liability cover can respond where a business unknowingly handles counterfeit stock, but where a business ignored warning signs such as prices significantly below market rate, cover may not respond. The Law Commission began a full review of the Consumer Protection Act 1987 in late 2025; any reform to that regime could affect how pharmacy clients are exposed and how underwriters price the risk. That makes supplier due diligence and pricing evidence material to both the client and the broker.

Broker Checklist Ahead of the November 18 NICE Ruling

The following steps are specific to the Foundayo launch and the November 18 NICE timetable.

• Before November 18, review life, travel and private medical insurance screening questions to verify they ask about weight-loss medication by name, including Foundayo and other GLP-1 products, rather than relying on a generic 'prescribed drugs' catch-all.
• Add a stop/restart question for GLP-1 use in application and suitability scripts, because Foundayo's once-daily no-fasting formulation gives clients no daily reminder that a prescription has changed.
• For pharmacy or distributor clients, document supplier due diligence and pricing checks; product liability cover may not respond where below-market prices or other warning signs were ignored, as the MHRA's Northampton warehouse cases show counterfeit weight-loss medicines are already in UK supply chains.
• Use the ABI's stated position that a policy taken out on inaccurate health information can be voided at claim stage when explaining disclosure duties, especially to clients within the Health Foundation's estimated 2.4 million UK GLP-1 users.
• Treat the NICE decision on November 18 as a trigger for reassessing underwriting question sets and product liability wordings; if NHS use is approved, the voluntarily disclosed cohort will not scale with the expanded patient population.